Under the Paperwork Reduction Act of 1995, no persons are requi to a collection of information unless it contains a valid OMB control number.

	Filing Date		10599432 2006-09-28	
NFORMATION DISCLOSURE	First Named Inventor Akihir		niro Toshima	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		N/A	
	Examiner Name	Not Y	et Assigned	
	Attornov Docket Numb	or.	20709/0205525 LISO	

		·			U.S.I	PATENTS	-		Remove	]	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	Date Name of Patentee or Applicant R		Releva		Lines where		
	1										
If you wisl	h to a	ı dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLK	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant Relevan			Columns,Lines where ant Passages or Releva s Appear		
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d button	_		
				FOREIG	GN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Re	or Relevant	т.
1	1	9813236	wo			1998-04-02	Budd Co				
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	button	Add		_
			NON	1-PATEN	NT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Initials*	Cite No	Include name of the ai (book, magazine, journ	nal, seria	al, symp	osium,	catalog, etc),					Тв

publisher, city and/or country where published.

#### 

1	

Attorney Docket Number

20708/0205525-US0

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Petert Documents at time USETO.GGU or MREP 991.94. \* Enter office that issued the document, by the to-relater ock (MPC)
Standard 57.3. \* "For uppersee petert occuments, the orbidates of the parent of the repart or present present or the parent of the parent
\*\*Kind of Gourner by the appropriate symbols as endicated on the document under WIPO Standard 57.1.6 if possible. \*\*Applicant is to place a check mark here it registed in application is a standard.\*\*

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10599432		
Filing Date			2006-09-28		
First Named Inventor Akihir		Akihir	o Toshima		
Art Unit			N/A		
	Examiner Name	Not Y	et Assigned		
Attorney Docket Number			20708/0205525-US0		

#### CERTIFICATION STATEMENT

Please see	37	CFR :	1 97	and	1 98 1	to make	the	appropriate	selection(s)	r

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/FB/ Flynn Barrison (53,970)	Date (YYYY-MM-DD)	2007-07-16
Name/Print	Louis I Delibidies	Pegistration Number	47522

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P. 0. Box 1440, Alexandria, V.S. 2231-1450. D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.2231-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the principal principal patients and the principal principal patients and the principal principal patients and the principal patients and the principal patients and the principal patients are patients. The principal patients are provided to the principal patients and the principal patients are patients. The principal patients are principally and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients and the patients are provided to the patients and the patients are principally as a patient patients are principally as a patient patients and the patients are principally as a principal patient patients. The patients are patients are patients and the patients are patients and the patients are patients and the patients are patients. The patients are patients are patients are patients and the patients are patients and the patients are patients are patients. The patients are patients are patients are patients and the patients are patients are patients are patients. The patients are patients. The patients are patients are patients ar

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.